Studied for
9 endpoints · 9 findings · 3 papers · 7 null
- Body masslowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- Fasting blood glucoseno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- HDL cholesterolno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- HOMA-IRno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
- LDL cholesterolno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
What the evidence says
How to read these marks9 findings · 9 endpoints · 3 papers · 7 null · by evidence strength
What moved
2 findings
Decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Overall weight loss was 1.27 kg (CI=-2.29 to -0.25) greater in ALA treatment compared to that in placebo group.”
Quoted verbatim from Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Adults in eight randomised, double-blind, placebo-controlled trials reporting weight, including patients with diabetes mellitus, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease and overweight or obesity; durations 8 to 52 weeks
Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.2017PMID:28295905Permalink
Increases total antioxidant capacity
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“ALA significantly improved TAC levels but had no effect on CRP.”
Quoted verbatim from Alpha-lipoic acid as a preventive measure in radiation-induced oral mucositis in head and neck cancer patients: A randomized controlled study.. - Study
- RCT
- Dose
- 600 mg twice daily
- Population
- Head and neck cancer patients receiving definitive radiotherapy, randomised to oral ALA or placebo tablets throughout the radiotherapy period
Alpha-lipoic acid as a preventive measure in radiation-induced oral mucositis in head and neck cancer patients: A randomized controlled study.2026PMID:41804854Permalink
What did not
7 findings
No detected effect on total cholesterol (TC)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
No detected effect on triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
No detected effect on fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
No detected effect on HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
No detected effect on HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
No detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
Show the remaining 1
No detected effect on C-reactive protein concentration
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“ALA significantly improved TAC levels but had no effect on CRP.”
Quoted verbatim from Alpha-lipoic acid as a preventive measure in radiation-induced oral mucositis in head and neck cancer patients: A randomized controlled study.. - Study
- RCT
- Dose
- 600 mg twice daily
- Population
- Head and neck cancer patients receiving definitive radiotherapy, randomised to oral ALA or placebo tablets throughout the radiotherapy period
Alpha-lipoic acid as a preventive measure in radiation-induced oral mucositis in head and neck cancer patients: A randomized controlled study.2026PMID:41804854Permalink
Papers screened
303 papers
- Compound
- lipoic acid
- Screened
- 303
- Admitted
- 3
- Discarded
- 42
- Not read
- 258
- Showing
- 200 of 303
Produced a finding3 papers
- PMID:282959052026-10-05
- PMID:401804162026-10-05
- PMID:418048542026-10-05
Discarded: the wrong intervention19 papers
- NCT00122447intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT00237718intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT00719706intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT01054768intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT01058941intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT01177189intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT01398943intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT01780974intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT02034422intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT02133664intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT02392767intervention×1 — no declared intervention names lipoic acid2026-09-29
- NCT02439879intervention×1 — no declared intervention names lipoic acid2026-09-29
and 7 more.
Discarded: another reason, stated per paper10 papers
- PMID:29979431no claim extracted — cause not determined2026-10-05
- PMID:42147097no claim extracted — cause not determined2026-10-05
- NCT00997438design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-29
- NCT01313117design×1 — allocation NA -- not randomised2026-09-29
- NCT01537549design×1 — allocation NA -- not randomised2026-09-29
- NCT01766219design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-29
- NCT01772758design×1 — allocation NON_RANDOMIZED -- not randomised2026-09-29
- NCT01902381design×1 — allocation NA -- not randomised2026-09-29
- NCT02484391design×1 — allocation NA -- not randomised2026-09-29
- NCT06787781design×1 — allocation NA -- not randomised2026-09-29
Discarded: no extractable result8 papers
- PMID:34465338claims extracted but refused by the deterministic validators2026-10-05
- PMID:40327515claims extracted but the two passes did not agree2026-10-05
- PMID:41917882no claim extracted — quote_over_cap2026-10-05
- NCT00090402declared_contrast×3 — no posted analysis compares a lipoic acid arm with a placebo/no-intervention arm and carries a p-value (Placebo=unmatched, Fish Oil=unmatched, Fish Oil Plus Lipoic Acid=EXPERIMENTAL+subject)2026-09-29
- NCT00962429declared_contrast×4 — no posted analysis compares a lipoic acid arm with a placebo/no-intervention arm and carries a p-value (Lipoic Acid=ACTIVE_COMPARATOR+subject, Placebo=PLACEBO_COMPARATOR+subject)2026-09-29
- NCT01188811declared_contrast×3 — no posted analysis compares a lipoic acid arm with a placebo/no-intervention arm and carries a p-value (Lipoic Acid=unmatched, Placebo=unmatched)2026-09-29
- NCT01221350declared_contrast×18 — no posted analysis compares a lipoic acid arm with a placebo/no-intervention arm and carries a p-value (Lipoic Acid=EXPERIMENTAL+subject, Placebo=PLACEBO_COMPARATOR)2026-09-29
- NCT03161028declared_contrast×4, outcome_node×1 — no posted analysis compares a lipoic acid arm with a placebo/no-intervention arm and carries a p-value (Lipoic Acid=unmatched, Placebo=unmatched)2026-09-29
Discarded: an endpoint this vocabulary does not hold5 papers
- PMID:37630823no claim extracted — no_outcome_node — measured: Total Symptom Score (TSS, 0 to 14.64) in diabetic sensorimotor polyneuropathy, pooled mean difference of change from baseline | Total Symptom Score in diabetic sensorimotor polyneuropathy, pooled mean difference; Neurological Disability Score; Neuropathy Impairment Score; global satisfaction odds ratio; vibration perception threshold; nerve conduction velocity2026-10-05
- PMID:37933068no claim extracted — no_outcome_node — measured: Total Symptom Score (TSS) in diabetic neuropathy, pooled SMD; also Neuropathy Symptoms and Change score (NSC) and Neuropathy Impairment Score (NIS) | Total Symptom Score in diabetic polyneuropathy, pooled SMD; Neuropathy Symptoms and Change score; Neuropathy Impairment Score (NIS), pooled SMD2026-10-05
- PMID:41397213no claim extracted — no_outcome_node — measured: walking speed on the Timed 25-Foot Walk, change over 24 months (ft/sec), linear mixed-effects model | walking speed on the Timed 25-Foot Walk, change over 24 months; whole-brain volume and deep gray matter volume by MRI2026-10-05
- PMID:42643396no claim extracted — no_outcome_node — measured: Total Symptom Score (TSS) in diabetic peripheral neuropathy, pooled mean difference; also NIS, NIS-LL and global satisfaction (risk ratio) | Total Symptom Score in diabetic peripheral neuropathy, pooled mean difference; Neuropathy Impairment Score and NIS-LL, pooled mean difference; global patient satisfaction, risk ratio2026-10-05
- NCT00477607outcome_node×2, commit×1 — "Ototoxicity Measurement" names no outcome in the closed vocabulary2026-09-29
Not read yet258 papers
- PMID:110024082026-09-29
- PMID:113139572026-09-29
- PMID:113230872026-09-29
- PMID:124391842026-09-29
- PMID:125213192026-09-29
- PMID:149914562026-09-29
- PMID:164847162026-09-29
- PMID:179828942026-09-29
- PMID:182668402026-09-29
- PMID:198870432026-09-29
- PMID:213580902026-09-29
- PMID:223296072026-09-29
and 246 more.
Measured, not recorded
- Compound
- lipoic acid
- Endpoints measured
- 326 endpoints
- Recorded as a finding
- No
Show what was measured
Body mass index change
decreases
A significant overall mean BMI difference was found -0.40 kg/m2 (CI=-0.76 to -0.03) between the ALA and placebo groups
PMID:28295905 · one of two readings recorded this
Body mass index change
no effect, p = 0.29
Meta-regression analysis showed no significant effect of ALA dose (P.E.=-0.16, CI=-0.48 to 0.14, p=0.29) on BMI change
PMID:28295905 · one of two readings recorded this
Body mass index change
decreases
Cumulative analysis of BMI reduction in ALA with diet interventions (-0.50 kg/m2 CI=-0.83 to -0.17) were similar to those ALA without diet interventions (-0.26 kg/m2 CI=-0.97 to -0.43)
PMID:28295905 · one of two readings recorded this
Body mass index change
no effect
Cumulative analysis of BMI reduction in ALA with diet interventions (-0.50 kg/m2 CI=-0.83 to -0.17) were similar to those ALA without diet interventions (-0.26 kg/m2 CI=-0.97 to -0.43)
PMID:28295905 · one of two readings recorded this
Body mass index change
decreases, p = 0.001
Intervention duration significantly affects BMI change (P.E.=-0.50, CI=-0.76 to -0.25, p<0.001)
PMID:28295905 · one of two readings recorded this
Body mass index change
no effect
Cumulative analysis of BMI reduction in weight loss interventions (-0.48 kg/m2 CI=-0.88 to -0.08) was similar to those non-weight loss interventions (-0.30 kg/m2 CI=-0.80 to 0.28)
PMID:28295905 · one of two readings recorded this
Body mass index change
decreases
Cumulative analysis of BMI reduction in weight loss interventions (-0.48 kg/m2 CI=-0.88 to -0.08) was similar to those non-weight loss interventions (-0.30 kg/m2 CI=-0.80 to 0.28)
PMID:28295905 · one of two readings recorded this
body mass index, kg/m2, mean difference ALA versus placebo
-0.40 kg/m2 (CI -0.76 to -0.03)
Not recorded as a finding: node body-mass-index exists but the Results sentence carries direction only as a signed estimate (-0.40); no direction word
A significant overall mean BMI difference was found -0.40 kg/m2 (CI=-0.76 to -0.03) between the ALA and placebo groups.
PMID:28295905 · one of two readings recorded this
body mass index, pooled mean difference between ALA and placebo
-0.40 kg/m2 (CI=-0.76 to -0.03)
Not recorded as a finding: Direction is carried only by the signed estimate; the sentence says a difference was found and gives -0.40 kg/m2 but no word for the direction (direction_not_in_words). The abstract prints -0.43, the Results -0.40.
A significant overall mean BMI difference was found -0.40 kg/m2 (CI=-0.76 to -0.03) between the ALA and placebo groups.
PMID:28295905 · one of two readings recorded this
Body weight change
decreases
Overall weight loss was 1.27 kg (CI=-2.29 to -0.25) greater in ALA treatment compared to that in placebo group
PMID:28295905 · one of two readings recorded this
Body weight change
no effect, p = 0.377
Meta-regression analysis showed that neither intervention duration (P.E.=-2.00, CI=-4.02 to 0.01, p = 0.051) nor ALA dose had a significant effect on weight change (P.E.=-0.956, CI=-3.08 to 1.16, p=0.377)
PMID:28295905 · one of two readings recorded this
Body weight change
decreases
we found no significant difference between body weight changes in ALA with diet intervention studies (-1.26 kg, CI=-2.14 to -0.37) compared to those only ALA intervention studies (-1.29kg, CI=-3.03 to 0.44)
PMID:28295905 · one of two readings recorded this
Body weight change
no effect
we found no significant difference between body weight changes in ALA with diet intervention studies (-1.26 kg, CI=-2.14 to -0.37) compared to those only ALA intervention studies (-1.29kg, CI=-3.03 to 0.44)
PMID:28295905 · one of two readings recorded this
Body weight change
no effect, p = 0.051
Meta-regression analysis showed that neither intervention duration (P.E.=-2.00, CI=-4.02 to 0.01, p = 0.051) nor ALA dose had a significant effect on weight change (P.E.=-0.956, CI=-3.08 to 1.16, p=0.377)
PMID:28295905 · one of two readings recorded this
Body weight change
no effect
we found no significant difference on effectiveness of ALA in weight loss interventions (-1.27, CI=-2.04 to -0.53) compared to those non-weight loss interventions (-1.14 CI=-2.99 to 0.69) (Q=0.01, d.f.=1, p=0.90)
PMID:28295905 · one of two readings recorded this
Body weight change
decreases
we found no significant difference on effectiveness of ALA in weight loss interventions (-1.27, CI=-2.04 to -0.53) compared to those non-weight loss interventions (-1.14 CI=-2.99 to 0.69) (Q=0.01, d.f.=1, p=0.90)
PMID:28295905 · one of two readings recorded this
side effects and withdrawal due to side effects, pooled odds ratios in three studies
no effect, side effects O.R.=1.25, CI=0.84 to 1.85; withdrawal O.R.= 0.43, CI=0.19 to 0.98
Not recorded as a finding: One sentence states no difference for both, but the withdrawal odds ratio given (0.43, CI 0.19 to 0.98) excludes 1, so the sentence contradicts its own interval and is not recorded.
Cumulative analysis of the percentage of subjects who experienced side effects (O.R.=1.25, CI=0.84 to 1.85) and withdrawal rates due to the side effects (O.R.= 0.43, CI=0.19 to 0.98) did not differ among the ALA and placebo groups.
PMID:28295905 · one of two readings recorded this
Subjects experiencing side effects
no effect
Cumulative analysis of the percentage of subjects who experienced side effects (O.R.=1.25, CI=0.84 to 1.85) and withdrawal rates due to the side effects (O.R.= 0.43, CI=0.19 to 0.98)
PMID:28295905 · one of two readings recorded this
Withdrawal due to side effects
no effect
Cumulative analysis of the percentage of subjects who experienced side effects (O.R.=1.25, CI=0.84 to 1.85) and withdrawal rates due to the side effects (O.R.= 0.43, CI=0.19 to 0.98)
PMID:28295905 · one of two readings recorded this
Clinical efficacy (markedly effective or effective)
increases, p = 0.00001
Compared with L monotherapy, F + L combination therapy for DPN also increased the efficacy significantly (RR 1.27, 95% CI 1.16–1.39, P <.00001)
PMID:29979431 · one of two readings recorded this
Clinical efficacy (markedly effective or effective)
increases, p = 0.00001
F + M combination therapy for DPN enhanced the efficacy obviously compared with M treatment (RR 1.26, 95% CI 1.17–1.35, P <.00001)
PMID:29979431 · one of two readings recorded this
clinical therapeutic efficacy (markedly effective / effective / ineffective), median and peroneal motor and sensory nerve conduction velocity, adverse events, for fasudil plus lipoic acid versus lipoic acid monotherapy in diabetic peripheral neuropathy
increases, efficacy RR 1.27, 95% CI 1.16–1.39 (fasudil + lipoic acid vs lipoic acid alone)
Not recorded as a finding: the comparison was against another active treatment
Compared with L monotherapy, F + L combination therapy for DPN also increased the efficacy significantly (RR 1.27, 95% CI 1.16–1.39, P <.00001).
PMID:29979431 · one of two readings recorded this
Median motor nerve conduction velocity (MNCV)
increases, p = 0.00001
Compared with monotherapy group, median MNCV showed significant improvement in the combination group (MD 6.69, 95% CI 4.74–8.64, P <.00001)
PMID:29979431 · one of two readings recorded this
Median sensory nerve conduction velocity (SNCV)
increases, p = 0.008
Compared with monotherapy, combination therapy increased median SNCV significantly (MD 6.71, 95% CI 1.77–11.65, P =.008)
PMID:29979431 · one of two readings recorded this
Peroneal motor nerve conduction velocity (MNCV)
increases, p = 0.00001
Compared with monotherapy, combination therapy accelerated peroneal MNCV significantly (MD 4.18, 95% CI 2.37–5.99, P <.00001)
PMID:29979431 · one of two readings recorded this
Peroneal sensory nerve conduction velocity (SNCV)
increases, p = 0.00001
Compared with monotherapy, combination therapy improved peroneal SNCV significantly (MD 5.89, 95% CI 3.57–8.20, P <.00001)
PMID:29979431 · one of two readings recorded this
β2-microglobulin (β2-MG)
decreases, p = 0.001
a remarkable decline in the level of β2-MG in DN patients treated with lipoic acid plus valsartan was found (P < 0.001, SMD = -2.59, 95%CI = -3.78 to − 1.40; P = 0.03, SMD = -0.48, 95%CI = -0.93 to − 0.04)
PMID:34465338 · one of two readings recorded this
high-sensitivity C-reactive protein, pooled SMD, lipoic acid plus valsartan versus valsartan or lipoic acid monotherapy
no effect, SMD = -2.80, 95%CI = -5.67 to 0.07; SMD = -0.42, 95%CI = -0.92 to 0.08
Not recorded as a finding: One sentence pools the comparison against valsartan alone (isolates lipoic acid) with the comparison against lipoic acid alone (tests valsartan), so it does not support a lipoic acid claim on its own.
We observed that there were no significant differences in hs-CRP level in DN patients receiving lipoic acid plus valsartan when compared with valsartan or lipoic acid monotherapy(P = 0.06, SMD = -2.80, 95%CI = -5.67 to 0.07; P = 0.10, SMD = -0.42, 95%CI = -0.92 to 0.08).
PMID:34465338 · one of two readings recorded this
hs-CRP, pooled SMD, lipoic acid plus valsartan versus monotherapy
no effect, SMD -2.80 (95% CI -5.67 to 0.07); SMD -0.42 (95% CI -0.92 to 0.08)
Not recorded as a finding: node c-reactive-protein exists but the sentence pools the comparator as valsartan or lipoic acid monotherapy, so valsartan-added contrast is mixed with the lipoic-acid-added contrast
We observed that there were no significant differences in hs-CRP level in DN patients receiving lipoic acid plus valsartan when compared with valsartan or lipoic acid monotherapy(P = 0.06, SMD = -2.80, 95%CI = -5.67 to 0.07; P = 0.10, SMD = -0.42, 95%CI = -0.92 to 0.08).
PMID:34465338 · one of two readings recorded this
Hypersensitive C-reactive protein (hs-CRP)
no effect, p = 0.06
there were no significant differences in hs-CRP level in DN patients receiving lipoic acid plus valsartan when compared with valsartan or lipoic acid monotherapy(P = 0.06, SMD = -2.80, 95%CI = -5.67 to 0.07; P = 0.10, SMD = -0.42, 95%CI = -0.92 to 0.08)
PMID:34465338 · one of two readings recorded this
Malondialdehyde (MDA)
decreases, p = 0.0002
Remarkable reduction of MDA was witnessed in patients received lipoic acid plus valsartan(P = 0.0002, SMD = -1.99, 95%CI = -3.02 to − 0.96; P = 0.0001, SMD = -0.69, 95%CI = -1.04 to − 0.34)
PMID:34465338 · one of two readings recorded this
serum malondialdehyde, pooled SMD, lipoic acid plus valsartan versus valsartan or lipoic acid monotherapy
decreases, SMD = -1.99, 95%CI = -3.02 to -0.96; SMD = -0.69, 95%CI = -1.04 to -0.34
Not recorded as a finding: Sentence merges the valsartan-alone and lipoic-acid-alone comparators; assay not stated (circulating MDA node records TBARS versus HPLC).
Remarkable reduction of MDA was witnessed in patients received lipoic acid plus valsartan(P = 0.0002, SMD = -1.99, 95%CI = -3.02 to − 0.96; P = 0.0001, SMD = -0.69, 95%CI = -1.04 to − 0.34).
PMID:34465338 · one of two readings recorded this
serum MDA level, pooled SMD, lipoic acid plus valsartan versus monotherapy
decreases, SMD -1.99 (95% CI -3.02 to -0.96); SMD -0.69 (95% CI -1.04 to -0.34)
Not recorded as a finding: node malondialdehyde-circulating exists but the sentence pools valsartan-alone and lipoic-acid-alone comparators and the assay is not stated
Remarkable reduction of MDA was witnessed in patients received lipoic acid plus valsartan(P = 0.0002, SMD = -1.99, 95%CI = -3.02 to − 0.96; P = 0.0001, SMD = -0.69, 95%CI = -1.04 to − 0.34).
PMID:34465338 · one of two readings recorded this
serum SOD level, pooled SMD, lipoic acid plus valsartan versus monotherapy
increases, SMD 1.24 (95% CI 0.32 to 1.03); SMD 0.68 (95% CI 0.32 to 1.03)
Not recorded as a finding: node superoxide-dismutase-activity exists but the sentence pools valsartan-alone and lipoic-acid-alone comparators; assay and sample matrix not stated
The results showed that lipoic acid combined with valsartan for the treatment of DN was much more effective in increasing the level of SOD than valsartan or lipoic acid monotherapy(P = 0.03, SMD = 1.24, 95%CI = 0.32 to 1.03; P = 0.0002, SMD = 0.68, 95%CI = 0.32 to 1.03).
PMID:34465338 · one of two readings recorded this
serum T-AOC level, pooled SMD, lipoic acid plus valsartan versus monotherapy
increases, SMD 0.89 (95% CI 0.62 to 1.16); SMD 0.58 (95% CI 0.10 to 1.07)
Not recorded as a finding: node total-antioxidant-capacity exists but the sentence pools valsartan-alone and lipoic-acid-alone comparators and the assay is not stated
Compared with valsartan or lipoic acid monotherapy, lipoic acid plus valsartan could markedly increase T-AOC levels (P < 0.00001, SMD = 0.89, 95%CI = 0.62 to 1.16; P = 0.02, SMD = 0.58, 95%CI = 0.10 to1.07).
PMID:34465338 · one of two readings recorded this
Superoxide dismutase (SOD)
increases, p = 0.03
lipoic acid combined with valsartan for the treatment of DN was much more effective in increasing the level of SOD than valsartan or lipoic acid monotherapy(P = 0.03, SMD = 1.24, 95%CI = 0.32 to 1.03; P = 0.0002, SMD = 0.68, 95%CI = 0.32 to 1.03)
PMID:34465338 · one of two readings recorded this
total antioxidant capacity (T-AOC) in serum, pooled SMD, lipoic acid plus valsartan versus valsartan or lipoic acid monotherapy
increases, SMD = 0.89, 95%CI = 0.62 to 1.16; SMD = 0.58, 95%CI = 0.10 to 1.07
Not recorded as a finding: Sentence merges the valsartan-alone and lipoic-acid-alone comparators; assay (FRAP or ABTS) not stated.
Compared with valsartan or lipoic acid monotherapy, lipoic acid plus valsartan could markedly increase T-AOC levels (P < 0.00001, SMD = 0.89, 95%CI = 0.62 to 1.16; P = 0.02, SMD = 0.58, 95%CI = 0.10 to1.07).
PMID:34465338 · one of two readings recorded this
Total antioxidant capacity (T-AOC)
increases, p = 0.00001
Compared with valsartan or lipoic acid monotherapy, lipoic acid plus valsartan could markedly increase T-AOC levels (P < 0.00001, SMD = 0.89, 95%CI = 0.62 to 1.16; P = 0.02, SMD = 0.58, 95%CI = 0.10 to1.07)
PMID:34465338 · one of two readings recorded this
Urinary albumin excretion rate (UAER)
decreases, p = 0.00001
Compared with valsartan monotherapy, treatment with lipoic acid plus valsartan could significantly reduce the UAER in patients with DN (P < 0.00001, SMD = -1.95, 95%CI = -2.55 to − 1.20)
PMID:34465338 · one of two readings recorded this
Urinary albumin
decreases, p = 0.001
Compared with valsartan or lipoic acid monotherapy, lipoic acid combined with valsartan could remarkably decrease the level of urinary albumin (P = 0.001, SMD = -1.48, 95%CI = -2.38 to − 0.58; P = 0.01, SMD = -1.67, 95%CI = -3.00 to − 0.33)
PMID:34465338 · one of two readings recorded this
Global satisfaction (good or very good)
increases
The pooled odds ratio of ALA administration at the dosages of 600, 1200, and 1800 mg/day was 2.15 (95% CI [1.58, 2.92]), 3.2 (95% CI [1.33, 7.71]), and 6.56 (95% CI [2.60, 16.54]), respectively
PMID:37630823 · one of two readings recorded this
Global satisfaction (good or very good)
increases
The pooled odds ratio of ALA administration at the dosages of 600, 1200, and 1800 mg/day was 2.15 (95% CI [1.58, 2.92]), 3.2 (95% CI [1.33, 7.71]), and 6.56 (95% CI [2.60, 16.54]), respectively
PMID:37630823 · one of two readings recorded this
Global satisfaction (good or very good)
increases
The pooled odds ratio of ALA administration at the dosages of 600, 1200, and 1800 mg/day was 2.15 (95% CI [1.58, 2.92]), 3.2 (95% CI [1.33, 7.71]), and 6.56 (95% CI [2.60, 16.54]), respectively
PMID:37630823 · one of two readings recorded this
Global satisfaction (good or very good)
increases
The odds ratio for overall global satisfaction was 2.48 (95% CI [1.88, 3.27]) relative to the placebo
PMID:37630823 · one of two readings recorded this
Neurological disability score (NDS)
decreases
ALA administration produced significantly more favorable NDS outcomes relative to the control (MD, −0.98; 95% CI [−1.29, −0.67]
PMID:37630823 · one of two readings recorded this
Neuropathy impairment score lower limb (NIS-LL)
no effect
VAS, MD [−0.32], 95% CI [−0.82, 0.19]; VPT, MD [−2.51], 95% CI [−7.40, 2.38]; NIS-LL, MD [−0.58], 95% CI [−1.27, 0.1]
PMID:37630823 · one of two readings recorded this
Neuropathy impairment score (NIS)
decreases
ALA administration produced significantly more favorable NIS outcomes relative to the placebo (MD, −1.16; 95% CI [−1.92, −0.41]
PMID:37630823 · one of two readings recorded this
Peroneal motor nerve conduction velocity (MNCV)
no effect
peroneal MNCV: MD, −0.13 and 95% CI [−0.82, 0.61]; sural SNAP: MD, 0.07 and 95% CI [−0.32, 0.46]
PMID:37630823 · one of two readings recorded this
Sural sensory nerve action potential (SNAP)
no effect
peroneal MNCV: MD, −0.13 and 95% CI [−0.82, 0.61]; sural SNAP: MD, 0.07 and 95% CI [−0.32, 0.46]
PMID:37630823 · one of two readings recorded this
total symptoms' score (TSS, 0 to 14.64) in diabetic sensorimotor polyneuropathy, pooled MD of oral ALA versus placebo; also NDS, NIS, NIS-LL, VPT, nerve conduction results, VAS pain, global satisfaction (odds ratio)
TSS MD, −1.69; 95% CI [−1.57, −1.08] (fixed-effect)
Not recorded as a finding: this platform holds no node for the endpoint
The pooled estimated effect, which was determined using a fixed-effect model, revealed that ALA administration led to significantly more favorable TSS outcomes relative to the control (MD, −1.69; 95% CI [−1.57, −1.08]).
PMID:37630823 · one of two readings recorded this
Total symptoms score (TSS)
decreases
The pooled estimated effect, which was determined using a fixed-effect model, revealed that ALA administration led to significantly more favorable TSS outcomes relative to the control (MD, −1.69; 95% CI [−1.57, −1.08])
PMID:37630823 · one of two readings recorded this
Vibration perception threshold (VPT)
no effect
VAS, MD [−0.32], 95% CI [−0.82, 0.19]; VPT, MD [−2.51], 95% CI [−7.40, 2.38]; NIS-LL, MD [−0.58], 95% CI [−1.27, 0.1]
PMID:37630823 · one of two readings recorded this
Visual analog scale of pain (VAS)
no effect
VAS, MD [−0.32], 95% CI [−0.82, 0.19]; VPT, MD [−2.51], 95% CI [−7.40, 2.38]; NIS-LL, MD [−0.58], 95% CI [−1.27, 0.1]
PMID:37630823 · one of two readings recorded this
Neuropathy impairment score, ALA600 oral versus oral placebo (pooled)
no effect, p = 0.22
These studies showed no significant difference in the pooled SMD estimate between oral ALA600 versus an oral placebo (SMD = −1.42, CI = −3.68 to 0.84, and P =.22)
PMID:37933068 · one of two readings recorded this
Neuropathy symptoms and change score, ALA600 oral versus oral placebo (pooled)
decreases, p = 0.01
These studies showed no significant difference in the pooled SMD estimate between oral ALA600 versus an oral placebo (SMD = −0.09, CI = −0.15 to −0.02, and P =.01)
PMID:37933068 · one of two readings recorded this
Total symptom score, ALA1800 oral versus oral placebo (pooled)
decreases, p = 0.0004
These studies showed no significant difference in the pooled SMD estimate between oral ALA1800 versus an oral placebo (SMD = −1.79, CI = −2.79 to −0.80, and P =.0004)
PMID:37933068 · one of two readings recorded this
Total symptom score, ALA600 IV versus IV placebo (pooled)
decreases, p = 0.00001
These studies showed no significant difference in the pooled SMD estimate between ALA600 IV versus a placebo IV (SMD = −3.59, CI = −4.16 to −3.02, and P <.00001)
PMID:37933068 · one of two readings recorded this
Total symptom score, ALA600 oral versus oral placebo (pooled)
decreases, p = 0.03
These studies showed no significant difference in the pooled SMD estimate between ALA600 ORAL and the oral placebo (SMD = −0.46, CI = −0.88 to −0.03, and P =.03)
PMID:37933068 · one of two readings recorded this
Fasting blood glucose
no effect, p = 0.39, n = 284
FBS | 7 | 284 | (−0.23, 0.38) | 0.2 | 2.90% (0.00% to 0.60%) | 0.04 | 0.125 (−0.16 to 0.41) | 0.39
PMID:40180416 · one of two readings recorded this
HOMA-IR
no effect, p = 0.23, n = 162
HOMA-IR | 5 | 162 | (−1.40, 1.83) | 0.25 | 57.70% (0.00% to 0.82%) | 0.05 | −0.225 (−0.60 to 0.15) | 0.23
PMID:40180416 · one of two readings recorded this
Triglycerides
no effect, p = 0.36, n = 567
TG | 8 | 567 | (−0.15, 0.26) | 0.81 | 0.00% (0.00% to 0.56%) | 0 | −0.078 (−0.24 to 0.09) | 0.36
PMID:40180416 · one of two readings recorded this
Triglycerides
no effect
Besides, ALA administered alone does not significantly impact TG levels
PMID:40180416 · one of two readings recorded this
Triglycerides
decreases
However, when ALA is combined with other components, it demonstrates a small yet significant positive effect on reducing TG levels (online supplemental figure S30)
PMID:40180416 · one of two readings recorded this
HDL-C
no effect, p = 0.52, n = 567
HDL-C | 8 | 567 | (−0.18, 0.23) | 0.56 | 0.00% (0.00% to 0.56%) | 0 | −0.054 (−0.22 to 0.11) | 0.52
PMID:40180416 · one of two readings recorded this
LDL-C
no effect, p = 0.37, n = 206
LDL-C | 6 | 206 | (−0.25, 0.51) | 0.45 | 0.00% (0.00% to 0.61%) | 0 | −0.126 (−0.40 to 0.15) | 0.37
PMID:40180416 · one of two readings recorded this
Total cholesterol and fasting blood glucose
modulates
In the overweight or obese group, ALA supplementation is associated with a slight reduction in TC and FBS
PMID:40180416 · one of two readings recorded this
Total cholesterol by ALA dose
decreases
high-dose ALA may have a slight effect on reducing TC, but the results are highly heterogeneous (online supplemental figures S19)
PMID:40180416 · one of two readings recorded this
Total cholesterol
no effect, p = 0.8, n = 411
TC | 6 | 411 | (−1.66, 1.39) | 0 | 84.40% (0.63% to 0.91%) | 0.52 | 0.083 (−0.55 to 0.71) | 0.8
PMID:40180416 · one of two readings recorded this
Sperm concentration
no effect, p = 0.063
There was a slight improvement in sperm concentration, but it was non-statistically significant (MD 11.99; CI 95% −0.67 to 24.66; p = 0.063; I2 = 92%; Figure-3C)
PMID:40327515 · one of two readings recorded this
Sperm concentration
no effect
5 | randomised trials | not serious | not serious | not serious | not serious | none | 131 | 119 | - | MD 11.99 higher (0.67 lower to 24.66 higher) | ⨁⨁⨁⨁ High | IMPORTANT
PMID:40327515 · one of two readings recorded this
abnormal sperm morphology, % of sperm
decreases, MD -0.89, 95% CI -1.48 to -0.29, p = 0.003
Not recorded as a finding: no outcome node for sperm morphology
Additionally, ALA was associated with a reduction of sperm abnormal morphology (MD −0.89; CI 95% −1.48 to −0.29; p = 0.003; I2 = 16%; Figure-3A).
PMID:40327515 · one of two readings recorded this
Ejaculation volume
no effect, p = 0.68
MD 0.14; CI 95% −0.54 to 0.83; p = 0.680; I2 = 88%; Figure-4A
PMID:40327515 · one of two readings recorded this
Ejaculation volume
no effect
4 | randomised trials | not serious | not serious | not serious | not serious | none | 107 | 95 | - | MD0.14 higher (0.54 lower to 0.83 higher) | ⨁⨁⨁⨁ High | IMPORTANT
PMID:40327515 · one of two readings recorded this
Pregnancy rate
no effect, p = 0.192
demonstrating that the supplementation was not associated with pregnancy rate changes (MD 2.28; CI 95% 0.66 to 7.85; p = 0.192; I2 = 0%; Figure-4B)
PMID:40327515 · one of two readings recorded this
Pregnancy rate
no effect
2 | randomised trials | not serious | not serious | not serious | not serious | none | 9/49 (18.4%) | 3/36 (8.3%) | RR 2.28 (0.66 to 7.85) | 107 more per 1000 (from 28 fewer to 571 more) | ⨁⨁⨁⨁ High | CRITICAL
PMID:40327515 · one of two readings recorded this
Sperm abnormal morphology
decreases, p = 0.003
ALA was associated with a reduction of sperm abnormal morphology (MD −0.89; CI 95% −1.48 to −0.29; p = 0.003; I2 = 16%; Figure-3A)
PMID:40327515 · one of two readings recorded this
Sperm abnormal morphology
decreases
3 | randomised trials | not serious | not serious | not serious | not serious | none | 68 | 58 | - | MD0.89 lower (1.48 lower to 0.29 lower) | ⨁⨁⨁⨁ !High | CRITICAL
PMID:40327515 · one of two readings recorded this
sperm concentration, million per mL, semen analysis
MD 11.99, 95% CI -0.67 to 24.66, p = 0.063
Not recorded as a finding: node sperm-concentration exists but the only sentence pairs a direction word with a non-significant estimate and no statement of absence in words
There was a slight improvement in sperm concentration, but it was non-statistically significant (MD 11.99; CI 95% −0.67 to 24.66; p = 0.063; I2 = 92%; Figure-3C).
PMID:40327515 · one of two readings recorded this
sperm concentration (pooled MD versus placebo in infertile men, 600 mg/day oral ALA); also pregnancy rate (number of pregnancies in the study period, not ultrasound-confirmed), sperm motility, morphology, vitality, ejaculation volume
sperm concentration MD 11.99; CI 95% −0.67 to 24.66; I2 = 92%, p = 0.063
Not recorded as a finding: the supporting sentence never names the compound
There was a slight improvement in sperm concentration, but it was non-statistically significant (MD 11.99; CI 95% −0.67 to 24.66; p = 0.063; I2 = 92%; Figure-3C).
PMID:40327515 · one of two readings recorded this
sperm progressive motility and sperm total motility, % by semen analysis
increases, progressive motility MD 12.43, total motility MD 13.49, p = 0.008
Not recorded as a finding: no outcome node for sperm motility
In our pooled analysis, the oral supplementation of ALA when compared to placebo demonstrated improvement in sperm progressive motility (MD 12.43; CI 95% 2.89 to 21.97; p = 0.011; I2 = 96%; Figure-2A) and sperm total motility (MD 13.49; CI 95% 3.52 to 23.46; p = 0.008; I2 = 93%; Figure-2B).
PMID:40327515 · one of two readings recorded this
Sperm progressive motility
increases, p = 0.011
sperm progressive motility (MD 12.43; CI 95% 2.89 to 21.97; p = 0.011; I2 = 96%; Figure-2A)
PMID:40327515 · one of two readings recorded this
Sperm progressive motility
increases
4 | randomised trials | not serious | not serious | not serious | not serious | none | 106 | 107 | - | MD12.43 higher (2.89 higher to 21.97 higher) | ⨁⨁⨁⨁ High | CRITICAL
PMID:40327515 · one of two readings recorded this
Sperm total motility
increases, p = 0.008
sperm total motility (MD 13.49; CI 95% 3.52 to 23.46; p = 0.008; I2 = 93%; Figure-2B)
PMID:40327515 · one of two readings recorded this
Sperm total motility
increases
5 | randomised trials | not serious | not serious | not serious | not serious | none | 131 | 119 | - | MD13.49 higher (3.52 higher to 23.46 higher) | ⨁⨁⨁⨁ High | CRITICAL
PMID:40327515 · one of two readings recorded this
sperm vitality (live sperm %) and ejaculation volume, semen analysis
no effect, vitality MD 4.42 (95% CI -3.17 to 12.02); volume MD 0.14 (95% CI -0.54 to 0.83)
Not recorded as a finding: no outcome node for sperm vitality or semen volume
The antioxidant supplementation did not change the sperm vitality or ejaculation volume when compared to placebo (MD 4.42; CI 95% −3.17 to 12.02; p = 0.254; I2 58%; Figure-3B; and MD 0.14; CI 95% −0.54 to 0.83; p = 0.680; I2 = 88%; Figure-4A, respectively).
PMID:40327515 · one of two readings recorded this
Sperm vitality
no effect, p = 0.254
(MD 4.42; CI 95% −3.17 to 12.02; p = 0.254; I2 58%; Figure-3B
PMID:40327515 · one of two readings recorded this
Sperm vitality
no effect
3 | randomised trials | not serious | not serious | not serious | not serious | none | 88 | 73 | - | MD4.42 higher (3.17 lower to 12.02 higher) | ⨁⨁⨁⨁ High | IMPORTANT
PMID:40327515 · one of two readings recorded this
Deep gray matter volume
unclear
Deep gray matter volume remained stable in LA participants and decreased in placebo participants
PMID:41397213 · one of two readings recorded this
Discontinuation from study
increases
LA participants discontinued from the study more often (37%) than placebo (17%)
PMID:41397213 · one of two readings recorded this
Mobility, other clinical and patient-reported outcomes
no effect
nor showed differences in mobility, other clinical, or patient-reported outcomes from placebo
PMID:41397213 · one of two readings recorded this
Walking speed decline (Timed 25-Foot Walk)
no effect
LA did not slow declines in walking speed (-0.39 ft/sec vs -0.30 ft/sec; -0.08 [-0.33 to 0.17])
PMID:41397213 · one of two readings recorded this
walking speed on the Timed 25-Foot Walk (primary outcome) over 24 months in progressive multiple sclerosis, 1,200 mg daily oral lipoic acid versus placebo; secondary brain atrophy, other clinical outcomes, adverse events including proteinuria
walking speed difference -0.08 [-0.33 to 0.17] (-0.39 ft/sec vs -0.30 ft/sec)
Not recorded as a finding: this platform holds no node for the endpoint
LA did not slow declines in walking speed (-0.39 ft/sec vs -0.30 ft/sec; -0.08 [-0.33 to 0.17]), nor showed differences in mobility, other clinical, or patient-reported outcomes from placebo.
PMID:41397213 · one of two readings recorded this
walking speed on the Timed 25-Foot Walk (primary), whole-brain and deep gray matter volume on MRI, EDSS and other clinical outcomes, proteinuria, in progressive multiple sclerosis, oral lipoic acid 1,200 mg daily versus placebo for 24 months
-0.08 [-0.33 to 0.17] ft/sec difference in decline of walking speed
Not recorded as a finding: this platform holds no node for the endpoint
LA did not slow declines in walking speed (-0.39 ft/sec vs -0.30 ft/sec; -0.08 [-0.33 to 0.17]), nor showed differences in mobility, other clinical, or patient-reported outcomes from placebo.
PMID:41397213 · one of two readings recorded this
Whole-brain volume
unclear
Whole-brain volume seemed stable in LA participants, whereas it trended toward a decrease in placebo
PMID:41397213 · one of two readings recorded this
Healing time of oral mucositis
decreases, p = 0.042
resulted in significantly shorter healing time (p value = 0.042)
PMID:41804854 · one of two readings recorded this
incidence of severe radiation-induced oral mucositis (RTOG grades 3 and 4), proportion of patients
decreases, 16.7% with ALA versus 41.3% in control, p = 0.036
Not recorded as a finding: no outcome node for radiation-induced oral mucositis incidence by RTOG grading
The incidence of severe RIOM was 16.7% with the use of ALA, while in the control group it was 41.3% (p value = 0.036).
PMID:41804854 · one of two readings recorded this
incidence of severe radiation-induced oral mucositis (RTOG grades 3 and 4)
decreases, 16.7% with ALA versus 41.3% in the control group, p = 0.036
Not recorded as a finding: No outcome node for radiation-induced oral mucositis incidence or severity on the RTOG grading system (primary endpoint).
The incidence of severe RIOM was 16.7% with the use of ALA, while in the control group it was 41.3% (p value = 0.036).
PMID:41804854 · one of two readings recorded this
Incidence of severe radiation-induced oral mucositis (RTOG grades 3 and 4)
decreases, p = 0.036
The incidence of severe RIOM was 16.7% with the use of ALA, while in the control group it was 41.3% (p value = 0.036)
PMID:41804854 · one of two readings recorded this
Onset of severe radiation-induced oral mucositis
increases, p = 0.033
ALA significantly delayed the occurrence of severe RIOM (p value = 0.033)
PMID:41804854 · one of two readings recorded this
Quality of life score, mean percent change from baseline
no effect
ALA resulted in a mean percent change in QOL score from baseline of 43.33, which was non-significantly different from the control group with a mean of 44.84
PMID:41804854 · one of two readings recorded this
Serum C-reactive protein (CRP)
no effect
ALA significantly improved TAC levels but had no effect on CRP
PMID:41804854 · one of two readings recorded this
Serum total antioxidant capacity (TAC)
increases
ALA significantly improved TAC levels but had no effect on CRP
PMID:41804854 · one of two readings recorded this
Fat mass
no effect
FM (WMD: 0.39, 95% CI: -1.10 to 1.88)
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
HOMA-IR (WMD: -0.18, 95% CI: -1.24 to 0.88)
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Age | ≥ 50 years | 2 | 0.39 (-0.81 to 1.58) | 71.4 | 0.061
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
BMI | ≥ 30 kg/m2 | 3 | 0.45 (-1.11 to 2.01) | 81.7 | 0.004
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Dose | 1200 mg | 2 | 0.11 (-2.11 to 2.32) | 88.0 | 0.004
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
≤ 400 mg | 3 | -0.34 (-1.75 to 1.08) | 97.5 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
≤ 12 weeks | 2 | 0.11 (-2.11 to 2.32) | 88.0 | 0.004
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Follow-up | ≥ 24 weeks | 3 | -0.34 (-1.75 to 1.08) | 97.5 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
FibroScan | 1 | 1.20 (-0.13 to 2.53) | - | -
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Liver biopsy | 1 | -0.07 (-0.17 to 0.03) | - | -
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Diagnosis of NAFLD | Ultrasonography | 3 | -0.58 (-2.26 to 1.10) | 91.9 | < 0.001
PMID:41917882 · one of two readings recorded this
HOMA-IR
no effect
Sample size | ≥ 50 participants | 3 | -0.34 (-1.75 to 1.08) | 97.5 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
TG (WMD: -17.27, 95% CI: -46.85 to 12.31)
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Age | ≥ 50 years | 2 | -4.03 (-17.66 to 9.60) | 30.6 | 0.230
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
BMI | ≥ 30 kg/m2 | 3 | -8.25 (-36.86 to 20.36) | 34.9 | 0.215
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Dose | 1200 mg | 2 | 1.97 (-46.82 to 50.76) | 55.8 | 0.133
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
≤ 400 mg | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
≤ 12 weeks | 2 | 1.97 (-46.82 to 50.76) | 55.8 | 0.133
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Follow-up | ≥ 24 weeks | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
FibroScan | 1 | -20.00 (-50.88 to 10.88) | - | -
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Liver biopsy | 1 | -1.00 (-3.96 to 1.96) | - | -
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Diagnosis of NAFLD | Ultrasonography | 3 | -21.59 (-73.79 to 30.60) | 82.8 | 0.003
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Sample size | ≥ 50 participants | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
WHR (WMD: 0.00, 95% CI: -0.01 to 0.02)
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Age | ≥ 50 years | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Dose | 1200 mg | 2 | 0.00 (-0.01 to 0.02) | 0.0 | 0.755
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
≤ 400 mg | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
≤ 12 weeks | 2 | 0.00 (-0.01 to 0.02) | 0.0 | 0.755
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Follow-up | ≥ 24 weeks | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Diagnosis of NAFLD | Ultrasonography | 2 | 0.00 (-0.01 to 0.02) | 0.0 | 0.755
PMID:41917882 · one of two readings recorded this
Waist-to-hip ratio
no effect
Sample size | ≥ 50 participants | 1 | -0.01 (-0.39 to 0.37) | - | -
PMID:41917882 · one of two readings recorded this
TNF-alpha
no effect
TNF-α (WMD: -1.17, 95% CI: -3.45 to 1.12)
PMID:41917882 · one of two readings recorded this
GGT
no effect
GGT (WMD: -32.40, 95% CI: -99.07 to 34.27)
PMID:41917882 · one of two readings recorded this
AST
no effect
AST (WMD: -0.49, 95% CI: -1.61 to 0.64)
PMID:41917882 · one of two readings recorded this
AST
no effect
Age | ≥ 50 years | 2 | -0.42 (-1.67 to 0.82) | 0.0 | 0.857
PMID:41917882 · one of two readings recorded this
AST
no effect
BMI | ≥ 30 kg/m2 | 3 | -0.81 (-3.23 to 1.62) | 0.0 | 0.984
PMID:41917882 · one of two readings recorded this
AST
no effect
Dose | 1200 mg | 2 | -0.78 (-3.40 to 1.84) | 0.0 | 0.866
PMID:41917882 · one of two readings recorded this
AST
no effect
≤ 400 mg | 2 | -0.42 (-1.67 to 0.82) | 0.0 | 0.857
PMID:41917882 · one of two readings recorded this
AST
no effect
≤ 12 weeks | 2 | -0.78 (-3.40 to 1.84) | 0.0 | 0.866
PMID:41917882 · one of two readings recorded this
AST
no effect
Follow-up | ≥ 24 weeks | 2 | -0.42 (-1.67 to 0.82) | 0.0 | 0.857
PMID:41917882 · one of two readings recorded this
AST
no effect
FibroScan | 1 | -1.00 (-7.40 to 5.40) | - | -
PMID:41917882 · one of two readings recorded this
AST
no effect
Liver biopsy | 1 | -0.40 (-1.67 to 0.87) | - | -
PMID:41917882 · one of two readings recorded this
AST
no effect
Diagnosis of NAFLD | Ultrasonography | 2 | -0.78 (-3.40 to 1.84) | 0.0 | 0.866
PMID:41917882 · one of two readings recorded this
AST
no effect
Sample size | ≥ 50 participants | 2 | -0.42 (-1.67 to 0.82) | 0.0 | 0.857
PMID:41917882 · one of two readings recorded this
Adiponectin
no effect
adiponectin (WMD: 1.84, 95% CI: -0.99 to 4.68)
PMID:41917882 · one of two readings recorded this
ALP
no effect
ALP (WMD: 21.13, 95% CI: -24.53 to 66.78)
PMID:41917882 · one of two readings recorded this
ALT
no effect
ALT (WMD: 1.43, 95% CI: -1.43 to 4.28)
PMID:41917882 · one of two readings recorded this
ALT
no effect
Age | ≥ 50 years | 2 | -0.06 (-1.44 to 1.32) | 0.0 | 0.440
PMID:41917882 · one of two readings recorded this
ALT
no effect
BMI | ≥ 30 kg/m2 | 3 | 0.99 (-5.51 to 7.49) | 17.9 | 0.296
PMID:41917882 · one of two readings recorded this
ALT
no effect
Dose | 1200 mg | 2 | 2.81 (-4.55 to 10.17) | 19.6 | 0.265
PMID:41917882 · one of two readings recorded this
ALT
no effect
≤ 400 mg | 3 | 1.17 (-2.33 to 4.66) | 60.3 | 0.080
PMID:41917882 · one of two readings recorded this
ALT
no effect
≤ 12 weeks | 2 | 2.81 (-4.55 to 10.17) | 19.6 | 0.265
PMID:41917882 · one of two readings recorded this
ALT
no effect
Follow-up | ≥ 24 weeks | 3 | 1.17 (-2.33 to 4.66) | 60.3 | 0.080
PMID:41917882 · one of two readings recorded this
ALT
no effect
FibroScan | 1 | -5.00 (-17.60 to 7.60) | - | -
PMID:41917882 · one of two readings recorded this
ALT
no effect
Liver biopsy | 1 | 0.00 (-1.39 to 1.39) | - | -
PMID:41917882 · one of two readings recorded this
ALT
no effect
Diagnosis of NAFLD | Ultrasonography | 3 | 3.76 (-0.66 to 6.86) | 0.0 | 0.516
PMID:41917882 · one of two readings recorded this
ALT
no effect
Sample size | ≥ 50 participants | 3 | 1.17 (-2.33 to 4.66) | 60.3 | 0.080
PMID:41917882 · one of two readings recorded this
AST/ALT ratio
no effect
AST/ALT (WMD: 0.03, 95% CI: -0.10 to 0.17)
PMID:41917882 · one of two readings recorded this
BMI
no effect
BMI (WMD: -0.36, 95% CI: -0.99 to 0.27)
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
FBI (WMD: -0.29, 95% CI: -2.95 to 2.36)
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
Age | ≥ 50 years | 2 | -0.37 (-1.33 to 0.59) | 0.0 | 0.827
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
Dose | 1200 mg | 2 | 0.10 (-9.56 to 9.76) | 87.9 | 0.004
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
≤ 400 mg | 2 | -0.37 (-1.33 to 0.59) | 0.0 | 0.827
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
≤ 12 weeks | 2 | 0.10 (-9.56 to 9.76) | 87.9 | 0.004
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
Follow-up | ≥ 24 weeks | 2 | -0.37 (-1.33 to 0.59) | 0.0 | 0.827
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
FibroScan | 1 | 0.00 (-3.44 to 3.44) | - | -
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
Liver biopsy | 1 | -0.40 (-1.40 to 0.60) | - | -
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
Diagnosis of NAFLD | Ultrasonography | 2 | 0.10 (-9.56 to 9.76) | 87.9 | 0.004
PMID:41917882 · one of two readings recorded this
Fasting blood insulin
no effect
Sample size | ≥ 50 participants | 2 | -0.37 (-1.33 to 0.59) | 0.0 | 0.827
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
FBS (WMD: 0.07, 95% CI: -3.08 to 3.21)
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
Age | ≥ 50 years | 2 | -1.57 (-5.33 to 2.18) | 3.0 | 0.310
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
BMI | ≥ 30 kg/m2 | 3 | 3.20 (-1.52 to 7.93) | 0.0 | 0.893
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
Dose | 1200 mg | 2 | 2.89 (-2.03 to 7.81) | 0.0 | 0.885
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
≤ 400 mg | 2 | -1.57 (-5.33 to 2.18) | 3.0 | 0.310
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
≤ 12 weeks | 2 | 2.89 (-2.03 to 7.81) | 0.0 | 0.885
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
Follow-up | ≥ 24 weeks | 2 | -1.57 (-5.33 to 2.18) | 3.0 | 0.310
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
FibroScan | 1 | 7.00 (-10.08 to 24.08) | - | -
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
Liver biopsy | 1 | -2.00 (-5.18 to 1.18) | - | -
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
Diagnosis of NAFLD | Ultrasonography | 2 | 2.89 (-2.03 to 7.81) | 0.0 | 0.885
PMID:41917882 · one of two readings recorded this
Fasting blood sugar
no effect
Sample size | ≥ 50 participants | 2 | -1.57 (-5.33 to 2.18) | 3.0 | 0.310
PMID:41917882 · one of two readings recorded this
Fat-free mass
no effect
FFM (WMD: 0.76, 95% CI: -0.25 to 1.76)
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
HDL-C (WMD: 1.25, 95% CI: -0.75 to 3.24)
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
Age | ≥ 50 years | 2 | 0.77 (-1.86 to 3.39) | 0.0 | 0.549
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
BMI | ≥ 30 kg/m2 | 3 | 1.19 (-2.33 to 4.72) | 21.4 | 0.280
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
Dose | 1200 mg | 2 | 1.49 (-3.03 to 6.01) | 48.7 | 0.163
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
≤ 400 mg | 2 | 0.77 (-1.86 to 3.39) | 0.0 | 0.549
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
≤ 12 weeks | 2 | 1.49 (-3.03 to 6.01) | 48.7 | 0.163
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
Follow-up | ≥ 24 weeks | 2 | 0.77 (-1.86 to 3.39) | 0.0 | 0.549
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
FibroScan | 1 | -2.00 (-11.42 to 7.42) | - | -
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
Liver biopsy | 1 | 1.00 (-1.74 to 3.74) | - | -
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
Diagnosis of NAFLD | Ultrasonography | 2 | 1.49 (-3.03 to 6.01) | 48.7 | 0.163
PMID:41917882 · one of two readings recorded this
HDL-C
no effect
Sample size | ≥ 50 participants | 2 | 0.77 (-1.86 to 3.39) | 0.0 | 0.549
PMID:41917882 · one of two readings recorded this
LDL-C
no effect
LDL-C (WMD: -0.11, 95% CI: -2.74 to 2.52)
PMID:41917882 · one of two readings recorded this
LDL-C
no effect
Age | ≥ 50 years | 2 | -0.10 (-2.80 to 2.60) | 0.0 | 0.991
PMID:41917882 · one of two readings recorded this
LDL-C
no effect
BMI | ≥ 30 kg/m2 | 3 | -0.22 (-9.98 to 9.54) | 0.0 | 0.694
PMID:41917882 · one of two readings recorded this
LDL-C
no effect
Dose | 1200 mg | 2 | -0.31 (-11.91 to 11.29) | 0.0 | 0.393
PMID:41917882 · one of two readings recorded this
LDL-C
no effect
≤ 400 mg | 2 | -0.10 (-2.80 to 2.60) | 0.0 | 0.991
PMID:41917882 · one of two readings recorded this
LDL-C
no effect
≤ 12 weeks | 2 | -0.31(-11.91 to 11.29) | 0.0 | 0.393
PMID:41917882 · one of two readings recorded this
Sources cited
3 papers
- Subject
- lipoic acid
- Findings
- 9
- Papers
- 3
Alpha-lipoic acid as a preventive measure in radiation-induced oral mucositis in head and neck cancer patients: A randomized controlled study.record2026PMID:418048542 findings
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.record2025PMID:401804166 findings
Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials.record2017PMID:282959051 finding